Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

Open access

Abstract

BACKGROUND: About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. However, such responses are rarely durable when conventional postremission therapy is administered. Uncontrolled trials have suggested that intensive postremission therapy may prolong these complete remissions. METHODS: We treated 1088 adults with newly diagnosed AML with three days of daunorubicin and seven days of cytarabine and randomly assigned patients who had a complete remission to receive four courses of cytarabine at one of three doses: 100 mg per square meter of body-surface area per day for five days by continuous infusion, 400 mg per square meter per day for five days by continuous infusion, or 3 g per square meter in a 3-hour infusion every 12 hours (twice daily) on days 1, 3, and 5. All patients then received four courses of monthly maintenance treatment. RESULTS: Of the 693 patients who had a complete remission, 596 were randomly assigned to receive postremission cytarabine. After a median follow-up of 52 months, the disease-free survival rates in the three treatment groups were significantly different (P = 0.003). Relative to the 100-mg group, the hazard ratios were 0.67 for the 3-g group (95 percent confidence interval, 0.53 to 0.86) and 0.75 for the 400-mg group (95 percent confidence interval, 0.60 to 0.94). The probability of remaining in continuous complete remission after four years for patients 60 years of age or younger was 24 percent in the 100-mg group, 29 percent in the 400-mg group, and 44 percent in the 3-g group (P = 0.002). In contrast, for patients older than 60, the probability of remaining disease-free after four years was 16 percent or less in each of the three postremission cytarabine groups. CONCLUSIONS: These data support the concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger. The results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199410063311402

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 62 references

Research works printed but not linked: 12

  1. Mayer RJ, 1987, Semin Oncol, 14, 25
  2. Schiffer CA, Mayer RJ. Cancer and Leukemia Group B (CALGB): studies in acute myeloid leukemia. In: Gale RP, ed. Acute myelogenous leukemia: progress and controversies. New York: Wiley-Liss, 1990:313-22.
  3. 1984, Lancet, 1, 1389
  4. Mayer RJ, 1982, Cancer Treat Rep, 66, 1455
  5. Skipper HE, 1964, Cancer Chemother Rep, 35, 1
  6. 10.2307/2281868 · doi:10.2307/2281868 · Paper page
  7. Bolwell BJ, 1988, Leukemia, 2, 253
  8. Mayer RJ, 1987, Semin Oncol, 14, 384
  9. Bishop JF, 1992, Prog Proc Am Soc Clin Oncol, 11, 260
  10. Wieck J, 1992, Prog Proc Am Soc Clin Oncol, 1, 261
  11. Preisler H, 1987, Blood, 69, 1441
  12. Gorin NC, 1991, Leukemia, 5, 896

Cited by

See all 1,427

Metadata

Authors
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E.
Affiliations
  • Harvard University (US)
  • University of Maryland, Baltimore (US)
  • Atrium Health Wake Forest Baptist (US)
  • North Shore University Hospital (US)
  • University of Alabama at Birmingham (US)
  • Duke Medical Center (US)
  • Dartmouth College (US)
Venue
New England Journal of Medicine
Published
1994-10-06
Volume
331
Issue
14
Pages
896-903
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2318674152
Cited by
1,427
References
62
Citations by year
2026: 9 · 2025: 33 · 2024: 18 · 2023: 28 · 2022: 30 · 2021: 43 · 2020: 41 · 2019: 34 · 2018: 25 · 2017: 47 · 2016: 30 · 2015: 38 · 2014: 50 · 2013: 59 · 2012: 58
FWCI
26.86
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (CA-33601, U10CA033601, U10CA032291, U10CA031983, CA 32291, CA 31983)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords
acute myeloid leukemia, cytarabine, daunorubicin, continuous infusion, high-dose cytarabine, dose-response relationship, disease-free survival, complete remission, maintenance therapy, age differences, adults, relapse risk, prognostic factors, prognostic score, risk stratification
MeSH terms
Acute Disease, Adolescent, Adult, Aged, Aged, 80 and over, Cytarabine, Daunorubicin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Leukemia, Myeloid, Male, Middle Aged, Remission Induction, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1056/nejm199410063311402
The paper
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994). Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia. New England Journal of Medicine. https://doi.org/10.1056/nejm199410063311402

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.